COMPANY PROFILE

Amwise Diagnostics

Developing patented genetic analysis technology to assist doctors and patients in determining the most appropriate individualized cancer treatment

TaiwanFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Amwise Diagnostics

Amwise Diagnostics specializes in advanced genomic diagnostics focused on breast cancer. The company serves healthcare providers, oncologists, and medical institutions by offering precise genomic tests that predict breast cancer recurrence and guide treatment decisions. Operating in the healthcare and biotechnology market, Amwise Diagnostics employs a B2B (business-to-business) model, generating revenue through the sale of diagnostic tests and related services to medical professionals and institutions. The company's core product is an 18-gene based clinical genomic model that provides accurate predictions for early-stage breast cancer recurrence, aiding in personalized treatment plans. By leveraging cutting-edge genomic research and technology, Amwise Diagnostics aims to improve patient outcomes and optimize treatment strategies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Taiwan
Employees: 3
Open positions: None listed
Dealroom signal: 58.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Feb 2020	$10M	$40M	Simcere Pharma	—
SERIES A✓Equity / VC	Jan 2016	—	—	Lippo Group · Alibaba Entrepreneurs Fund · WI Harper Group	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Amwise Diagnostics website traffic

Latest recorded traffic for Amwise Diagnostics is 270 monthly website visits, down 48.1% over the last three months. Amwise Diagnostics's team grew 0% over the past year.

Latest monthly visits270 3-month web change-48.1% 1-year team growth0%

Monthly website visitsFeb 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
DEDeuterOncologyDeuterated MET kinase inhibitor for targeted cancer therapy	Liège, Belgium	Acquired
ASASYLIACompanion Diagnostics For Immunotherapy \| Asylia Diagnostics	Beerse, Belgium	Operational
IAImagene AIAI-based molecular testing for cancer	Tel Aviv-Yafo, Israel	Operational
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
PBPersephone BiosciencesSynthetic biology company developing a platform to industrialize and scale the microbiome	San Diego, United States	Operational
EBEisbach BioInnovative start-up in biotechnology developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes	Planegg, Germany	Operational
VIVitroScanDedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients	Leiden, Netherlands	Operational